Neurotensin (NTS) has long been recognized as a neurotransmitter or neuromodulator in the central nervous system and as an endocrine agent in the periphery via actions mediated through neurotensin receptors (NTSRs). Many studies support a role for NTS in the endocrine, autocrine and paracrine growth stimulation of cancer, with oncogenic actions described for NTS in different types of cancers and cancer cell lines at each step of cancer progression, ranging from tumour growth and survival to metastatic spread. The mechanisms underlying the effects of the NTS/NTSR system in cell proliferation, migration and invasion, as well as the anti-apoptotic effects of this system, have been elucidated in different types of cancers, and include mitogen-activated protein kinases, phosphatidylinositol 3-kinase and RhoGTPases. The present mini review summarizes recent findings relating to the oncogenic function of the NTS/NTSR system.
| INTRODUCTION
Neurotensin (NTS) is a tridecapeptide that acts as neurotransmitter or neuromodulator in the central nervous system (CNS), which has been related to CNS physiology and pathology, such as potent hypothermia, opioid-independent analgesia, Parkinson's disease and Schizophrenia.
In the periphery, NTS as a local hormone, has a detrimental effect by contributing to fat storage, obesity and metabolic disorders.
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Among the diverse biological effects of NTS is an ability to promote the growth of tissue, this effect not only indicates a role for NTS in the regulation of normal tissue growth, but also suggests that NTS could contribute to the growth of cancers. Neurotensin exerts its effects primarily through two-seven-transmembrane G-protein-coupled receptors (GPCR), namely high-affinity neurotensin receptor 1 (NTSR1) and low-affinity neurotensin receptor (NTSR2), as well as through NTSR3 (Sortilin 1), a single transmembrane domain sorting receptor. 4 The oncogenic action of NTS has been described in different types of cancers with effects at each step of progression from tumour growth (ie cell proliferation and anti-apoptotic effects), to metastatic spread (eg anchorage-independent growth and pro-migratory and pro-invasion effects). 5 These effects come about as a result of the dysregulation of NTS and NTSRs during the early stages of cell transformation; therefore, NTS and NTSRs have been established as markers of prognosis and diagnosis and pharmacological targets in various cancers. 6 This mini review summarizes the different information available regarding the oncogenic effects of the NTS/NTSR complex, and the signalling pathways associated with this complex in order to shed light on the significant role of this complex in tumour progression, and its potential as prognostic markers, diagnostic markers and therapeutic targets in some cancers.
| NEUROTENSIN
Neurotensin is a 13-amino acid peptide that is produced from a single precursor, pre-pro-neurotensin, which gives rise to both NTS and the related peptide neuromedin N. 
| NEUROTENSIN RECEPTORS
The key event underlying the role of NTS in malignant progression is the dysregulation of NTSRs in cancers. The action of NTS are mediated by two GPCRs, namely NTSR1 and NTSR2, as well as by NTSR3
(sortilin 1), of these receptors, NTSR1 has been extensively studied.
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It has been established that NTSR1 is more responsible for tumour progression, and acts as potential progressive biomarker or pharmacological target in selective cancers. 4, 6 Abnormal expression of NTSR1 appears in the early stages of cell transformation, for example, in colonic adenomas, the mutation or loss of adenomatous polyposis coli The NTSR2 receptor is a 410-amino acids protein, which shares approximately 64% homology with NTSR1. 13 The NTSR2 receptor has a lower affinity for NTS than NTSR1, and NTS binding to NTSR2 can be inhibited by levocabastine (a non-peptide histamine H1 receptor antagonist). 14 The expression of NTSR2 in cancer has been reported in prostatic cancer, B cells from chronic lymphocytic leukemia (CLL) and glioma. [15] [16] [17] There is little information about the biofunction and underlying mechanisms of NTSR2 activation in NTS-induced cancer progression. However, it has been demonstrated that NTS, levocabastine and SR48692 can trigger a calcium-dependent inward current in
Xenopus laevis oocytes transfected with mouse NTSR2 cDNA. 4 In ad- 
| ONCOGENIC EFFECTS OF NTS/NTSRS
There are many signal transduction pathways that mediate the main effects of NTS and they have been studied in different types of cancer, including non-small cell lung cancers (NSCLC), pancreatic adenocarcinomas, prostate cancers, hepatocellular carcinoma, colon tumours, breast cancers, and gliomas. [23] [24] [25] [26] [27] [28] [29] Neurotensin participates in each step of cancer progression, from survival and growth to metastatic spread, with all these cellular events activated because of the abnormal expression of NTSRs.
| Lung cancers
High concentrations of NTS and NTSR1 are present in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) compared with normal tissue. 30 NTSR1 expression is strongly associated with worse 5-year overall survival and relapse-free survival rates; the interactions between NTS and NTSR1 induce tumour progression by causing epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2/3 (HER 2/3) overexpression and activation. 31 In NSCLC, NTSR1 expression is an independent negative prognostic factor, NTS enhances tumour growth and products massive nodal metastasis; while, silencing of NTSR1 or SR48692 (NTR1 antagonist) treatment induces a reduction in tumour growth in vivo. 23, 32 In SCLC, SR48692 treatment inhibits NTS-mediated cell proliferation and tumour growth in vitro and in vivo. 
| Prostate cancers
It has been established that NTS is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. 34 The NTSRs, especially NTSR1 is described to be overexpressed in prostate cancer compared with normal samples. 16 In bicalutamide resistant prostate cancer, NTS stimulates an increased proliferation rate, cell cycle progression and invasiveness through matrigel, these effects could be reduced using siRNA knockdown of NTS. 35 The mechanisms of NTS stimulates mitogenesis in prostate cancer cells by a protein kinase C (PKC)-dependent ligand-mediated transactivation of EGFR, which led to stimulation of the Raf-mitogen-activated protein kinase (MEK)-ERK pathway in a phosphatidylinositol 3 (PI3) kinase-dependent manner.
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In addition, Ca 2+ is required for NTS to stimulate DNA synthesis and to enhance cAMP formation, and these effects are inhibited by the Ca 2+ channel blockers ( Figure 1 ). 
| Colorectal cancer
Neurotensin receptor is overexpressed in human colon cancer but not in normal colonic epithelium. 38 Increased NTSR1 expression is an early event during colonic tumourigenesis, contributing to tumour progression and aggressive tumour behaviour in colonic adenocarcinomas. 39 In vitro, NTS stimulates NTSR1, and then induces the proliferation of human colon cancer cell lines by stimulating MAPK/ERK signalling or in a post-transcription manner. 40, 41 In vivo, NTS promotes tumour growth through NTSR1, and these effects are inhibited by SR48692.
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In addition, sNTSR3, shed from the extracellular domain of NTSR3, is responsible for cancer metastasis by inducing the first phase of a process that wakens the desmosome architecture, leading to cell spreading and initiation of cell separation. 
| Pancreatic cancer
There is high expression of NTSR1 in pancreatic cancers compared with normal tissue, which is positively correlated with pathological grading. 43 In human pancreatic ductal adenocarcinoma cell line PANC-1, NTS-induced DNA synthesis and cell proliferation is PKCdependent. 44 In addition, PKC-mediated stimulation of ERK-1 and ERK-2 also play a pivotal role in NTS-induced growth of PANC-1 cells. 45 These stimulatory effects of NTS on the cell proliferation of pancreatic cancer cells are inhibited by SR48692. cells, the effects of NTS are mediated through EGFR/ERK signalling pathways, whereas in collectively migrating cells, the effects of NTS are dependent on the PI3K pathway. 
| Breast cancers
Neurotensin and NTSR1 are upregulated in breast cancers compared with normal breast tissue, and NTSR1 overexpression has been shown to predict a poor prognosis in terms of 5-year overall survival in invasive breast carcinomas. 28 The NTS/NTSR1 enhances the tumour growth and metastasis in experimental mice model, however, the NTS-mediated growth-promoting action is reduced by NTSR1 antagonist. 49 In addition, NTS treatment has been show to significantly inhibit the apoptosis of breast cancer cells overexpressing NTSR1, with the underlying mechanism involving increases in Bcl-2 mRNA and protein levels that are dependent on the MAPK pathway. 50 In addition, immunohistochemistry experiments performed in a cohort of clinical breast cancers and normal breast tissues reveal an increase in the expression of NTSR3 associated with breast cancer aggressiveness, particularly in ductal invasive carcinomas and in association with lymph node invasion. In melanoma cells, NTSR1 is usually highly expressed and plays an important role in cell cycle regulation, cell apoptosis and tumour growth in vitro and in vivo, while, SR48692 reduces cell proliferation and the self-renewal potential of these cells. 54 Together, the results of these studies suggest that, in addition to having anti-apoptotic effects, NTS and NTSRs may enhance the growth, migration and invasion of glioma, melanoma and colon, breast, lung, prostate, pancreatic, gastric, hepatic and head and neck cancers.
| ONCOGENIC SIGNALLING
There are multiple signalling transduction pathways mediating the effects of NTS/NTSRs on cell proliferation, survival, migration and invasion that are cell dependent and have been described in various types of cancers.
The NTSR1 is mostly coupled to the Gɑq/11 subunit, the binding of which activates PLC, followed by hydrolysis of membranous phosphati- and c-myc. 45 In addition, NTS activates protein kinase D (PKD) in a PKC-dependent manner and the activated PKD promotes the expression of nuclear factor (NF)-kB expression, with the role of NTSR1 in these effects being confirmed. 56 The NTSR3 coreceptor participating in NTS/NTSR1 signalling has been shown to form heterodimers with NTSR1, with the NTSR1/NTSR3 complex activating the MAPK/ERK and PI3K/AKT pathways. 19 The stimulatory effect of NTS on NF-kB expression also correlates with its ability to increase IP3 levels and to mobilize intracellular Ca
2+
; NF-kB induces miR-21 expression, which leads to decreased expression of phosphatase and tensin homologue (PTEN), a negative regulator of AKT activity, with AKT signalling one of the primary pathways commonly implicated in cancer development.
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Another pathway involved in the pro-migratory or pro-invasive effects of NTS involves the small RhoGTPases, such as Rac1, RhoA and Cdc42, these RhoGTPases are responsible for the cytoskeleton dynamics known to contribute to the formation of various cytoplasmic extensions like lamellipodia, filopodia, pseudopodia, or invadopodia. 57 Neurotensin and sNTSR3 induce FAK, 21 and NTS/NTSR1 complex activates the IL-8/CXCR1 signalling, which stimulates Janus tyrosine kinase (JAK) and subsequently promotes STAT3 activity. 53 
| CONCLUSION
The NTS and NTSR system provide insights into certain oncological situation. Neurotensin and NTSRs are over-activated in many cancers, and have been shown to be involved in each step of cancer progression. Thus, they may be diagnostic and predictive markers, as well as potential chemotherapeutic targets. Future studies should focus on the large-scale expression of NTS/NTSRs in diverse cancers in order to clarify the characteristics of NTS and NTSRs as prognostic or diagnostic markers. In addition, NTS/NTSRs may also be considered to become therapeutic targets for therapy purpose.
